Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Amerikaanse aandelen« Terug naar discussie overzicht

Amyris

244 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 13 »» | Laatste | Omlaag ↓
  1. [verwijderd] 2 december 2016 14:49
    En alweer een mooi Amyris-bericht (van gisteren 1 dec , maar was hier nog niet geplaatst):

    Amyris Signs Multi-Year Collaboration Extension with Kuraray
    Thu December 1, 2016 8:30 AM|GlobeNewswire|About: AMRS
    GlobeNewswire
    EMERYVILLE, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it has executed with its long-time partner Kuraray Co., LTD (TYO:3405) a multi-year extension to their collaboration agreement for the use of Amyris’s Biofene® branded ß-Farnesene in liquid farnesene rubber (“LFR”) and farnesene-based elastomer applications. This collaboration, which originally began in 2011, features increased farnesene supply to Kuraray and joint marketing of products to industry and end-customers.

    Amyris’s sugar cane-derived Biofene forms the basis for a wide range of products varying from specialty products such as cosmetics, perfumes, detergents and industrial lubricants, to transportation fuels such as diesel and jet fuel. As a tailor made pure hydrocarbon it provides numerous advantages when compared to petroleum-based oils and chemicals and is renewable, contributing to a sustainable future.

    Farnesene Fueling Better Products Across the World – Including Tires

    Kuraray’s recent technological successes with rubber containing farnesene includes an enhanced synthetic additive for tire manufacturers. Its novel LFR and other farnesene- containing rubber materials add substantial grip and cornering capability to tires, particularly in cold, snow and ice conditions. In addition, its hydrogenated styrenic-farnesene copolymer (“HSFC”) has demonstrated superior shock absorption in products ranging from footwear to specialty construction materials.

    “We are delighted to extend our relationship with Kuraray,” said John Melo, CEO of Amyris. “Introducing a novel molecule to industry requires patience and creativity. However, Kuraray’s technical expertise and customer relationships have reached the point where their products are now becoming mainstream and this, in turn, is fueling further broadening market adoption of our farnesene for a variety of products.”

    “Kuraray has many years’ experience working with farnesene, which we believe has many end-market applications,” said Mr. Kenichi Abe, President of Kuraray’s Isoprene business. “Our collaboration with Amyris and their breakthrough-ability to produce farnesene at industrial scale, and at competitive price, enables Kuraray to provide its customers products with superior performance and that are renewably sourced.”
  2. nobahamas 13 december 2016 15:34
    Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced it has signed a definitive agreement to establish a cosmetic ingredients joint venture with NIKKOL GROUP ('NIKKOL'), a leading Japanese cosmetic specialty chemical provider. NIKKOL is purchasing 50% of the Amyris Neossance business for up to $20 million in total. Amyris will receive $10 million of the purchase price upfront and the remaining $10 million is structured as an earn out over the first three years of the joint venture operation.
    www.twst.com/update/amyris-inc-amyris...
  3. nobahamas 14 december 2016 16:19
    Chevron Products Company, a division of Chevron U.S.A. Inc., and Novvi LLC today announced that Chevron has made an equity investment into Novvi LLC (a joint venture of Amyris, Inc. (Nasdaq:AMRS), Cosan S.A., and American Refining Group (ARG)). Terms of the transaction were not disclosed.
    globenewswire.com/news-release/2016/1...
  4. [verwijderd] 16 december 2016 21:12
    Mogelijk ten overvloede, maar misschien nuttig Amyris geinteresseerden te attenderen op een SA draadje, waar nog steeds (ook vandaag) commentaar aan toegevoegd wordt:

    seekingalpha.com/article/4029506-amyr...

    Niet heel veel nieuws maar wellicht nuttig te lezen wat bijvoorbeeld de twijfels van enkele Amerikaanse beleggers zijn (hoge schuld, onvoldoende productiecapaciteit, de nog steeds doorgaande verkoop van Amyris aandelen door een grootaandeelhouder etc.
  5. [verwijderd] 4 januari 2017 12:04
    Ja, Singular Research (wat ik als een zeer gedegen partij beschouw) is heel positief, da's mooi maar belangrijk is ook een van de reacties op dit artikel. Ene Apdamico stelt de volgende vraag aan Singular Research:

    Could you please explain John Melo's comments, during a December 2016 conference, in which he stated that because of the derivative effect, earnings are inversely affected by higher stock prices?
    That comment, which I do not understand, the production being at capacity (with no immediate resolution) and the companies' balance sheet seem to be holding the stock price down.
    Appreciate any color you may be able to provide concerning the derivative effect.
    Thank you for your article and positive outlook!


    Nog geen antwoord van Singular Research op deze zinvolle vraag (kan me voorstellen dat daar wat extra speurwerk voor nodig is), maar ik vind dat zelf wel relevant voor een verdere 'de-risking' van het aandeel Amyris. Mijn advies is dit toch goed in de gaten te houden (kan dus via de hierboven gegeven link).
244 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 13 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.